No Association Between COMT Val158Met Polymorphism and Prostate Cancer Risk: A Meta-Analysis

2013 ◽  
Vol 17 (1) ◽  
pp. 78-84 ◽  
Author(s):  
Li-wei Zou ◽  
Xiao-juan Xu ◽  
Ting Liu ◽  
Han-yong Wang ◽  
Wen-jing Fan ◽  
...  
2020 ◽  
Author(s):  
Pradeep Kumar ◽  
Vandana Rai

AbstractProstate cancer is one of the most common and a serious malignancy of males and it is well reported that estrogen plays a pivotal role in prostate carcinogenesis. Catechol-O - methyltransferase (COMT) catalyzes the inactivation of estrogens. Several studies have investigated the association of COMT gene Val158Metpolymorphism with prostate cancer, but results were inconsistent and inconclusive. Hence, to assess this association, we performed a meta-analysis of all published case-control studies. Pubmed, Springer link, Google Scholar, Elsevier and Springer link databases were searched for case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) was used as association measure. Statistical analysis was performed with the software program MIX and MetaAnalyst. In the current meta-analysis, 11 case control studies with 3381 prostate cancer cases and 3,276 healthy controls were considered. The results indicated no significant association between COMT Val158Met polymorphism and prostate cancer risk using allele contrast, co-dominant and homozygote models (allele contrast: OR= 0.92; 95% CI 0.85 to 0.98=; p= 0.02; co-dominant: OR=0.81; 95% CI= 0.85 to1.07; p= 0.46; homozygote: OR= 0.81; 95% CI= 0.70 to 0.95, p= 0.008), but showed significant association with dominant and recessive models (dominant: OR 1.18=; 95% CI= 1.03 to1.34; p= 0.01; recessive: OR= 1.54; 95% CI= 1.1 to 2.07; p = 0.003). In subgroup analysis meta-analysis using recessive genetic model showed significant association between COMT Val 158Met polymorphism and prostate cancer risk in both Asian and Caucasian populations. In conclusion, results of present meta-analysis supports that the COMT Val158Met polymorphism is risk factor for prostate cancer.


2016 ◽  
Vol 31 (2) ◽  
pp. 110-117 ◽  
Author(s):  
Yang Chen ◽  
Xiaoxiang Yu ◽  
Tianyu Li ◽  
Haibiao Yan ◽  
Zengnan Mo

Background Urological cancers occur worldwide. Many factors, among which the catechol-O-methyltransferase (COMT) Val158Met polymorphism, are said to be associated with the cancer risk. We conducted a meta-analysis to investigate the association between urological cancer susceptibility and COMT Val158Met in different genetic models. Methods This study was based on material obtained from the PubMed, HuGENet and Embase databases. Four models including dominant (AA + AG vs. GG), recessive (AA vs. AG + GG), codominant (AA vs. AG, AA vs. GG) and per-allele analysis (A vs. G) were applied. Odds ratios (OR) and the corresponding 95% confidence intervals (CI) were used to evaluate the power of the associations. Results Fourteen eligible studies comprising 3,285 cases and 3,594 controls were included. Although we could not detect a positive function of the COMT Val158Met polymorphism in urological cancers, the polymorphism might be significantly associated with bladder cancer risk (dominant model [AA + AG vs. GG]: OR = 0.736, 95% CI = 0.586-0.925, I2 = 0.00%; recessive model [AA vs. AG + GG]: OR = 0.822, 95%CI = 0.653-1.035, I2 = 6.30%; codominant model [AA vs. AG]: OR = 0.908, 95% CI = 0.710-1.161, I2 = 0.00%; codominant model [AA vs. GG]: OR = 0.693, 95% CI = 0.524-0.917, I2 = 30.20%; allele analysis [A vs. G]: OR = 0.826, 95%CI = 0.717-0.951, I2 = 30.20%). The same significant associations were not found for kidney cancer and prostate cancer risk in different ethnicities. There also seemed to be no distinct effect of the polymorphism on benign prostatic hyperplasia. Conclusions We suggest that bladder cancer but not prostate cancer and kidney cancer could be significantly associated with the Val158Met polymorphism. Interaction of COMT genetic and related environmental factors for urological cancers should not be ignored in future.


2015 ◽  
Vol 67 (3) ◽  
pp. 392-400 ◽  
Author(s):  
Huan Liu ◽  
Guang-Hui Hu ◽  
Xing-Chun Wang ◽  
Tian-Bao Huang ◽  
Liang Xu ◽  
...  

2016 ◽  
Vol Volume 9 ◽  
pp. 4163-4171 ◽  
Author(s):  
Yong Xu ◽  
Yungkai Qie ◽  
Xuewu Nian ◽  
Xuesen Liu ◽  
Hailong Hu ◽  
...  

2012 ◽  
Vol 14 (4) ◽  
pp. 560-565 ◽  
Author(s):  
Jie Yang ◽  
Dong-Liang Xu ◽  
Qiang Lu ◽  
Zhi-Jian Han ◽  
Jun Tao ◽  
...  

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0206249 ◽  
Author(s):  
Xian Zhang ◽  
Yi Lin ◽  
Xiaoning Xie ◽  
Meiya Shen ◽  
Guoping Huang ◽  
...  

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zheng-Ju Ren ◽  
De-Hong Cao ◽  
Qin Zhang ◽  
Peng-Wei Ren ◽  
Liang-Ren Liu ◽  
...  

2017 ◽  
Vol 19 (6) ◽  
pp. 666 ◽  
Author(s):  
Lu Yang ◽  
Qiang Wei ◽  
Ping Tan ◽  
Chen Zhang ◽  
Shi-You Wei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document